Audience -All Patients & Families-Adults & Aging-Chapters-Donors & Supporters-Healthcare Providers-Kids & Young Adults-Men-Payers-Spanish Speaking Individuals-Undiagnosed-Women & Girls Type of Bleeding Disorder -All Bleeding Disorders-Hemophilia-Inhibitors-Rare Bleeding Disorders-Von Willebrand Disease Topic -Advocacy-Awareness-Blood & Product Safety-Bone & Joint Health-Community-COVID-19-Digital Health-Diversity, Equity & Inclusion-Fitness & Nutrition-Future Therapies-Health Equity-Healthcare Insurance-HIV & Hepatitis C-Mental Health-Pain Management-Sexual & Reproductive Health-Research-Treatment & Care 25 Jan Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A Jan 25, 2023 - Jan 25, 2023 18 Jan inSourceRX Prescription Savings Jan 18, 2023 - Jan 18, 2023 11 Jan VWD Guidelines: Second Anniversary Update Jan 11, 2023 - Jan 11, 2023 14 Dec Efanesoctocog: A Truly Long-Acting FVIII Replacement Product Dec 14, 2022 - Dec 14, 2022 07 Dec Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays Dec 7, 2022 - Dec 7, 2022 30 Nov Giving Tuesday Highlight & The Importance of End-of-Year Giving Nov 30, 2022 - Nov 30, 2022 16 Nov VWD and Joint Bleeds Nov 16, 2022 - Nov 16, 2022 26 Oct Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A Oct 26, 2022 - Oct 26, 2022 19 Oct What's At Stake With The Upcoming Elections Oct 19, 2022 - Oct 19, 2022 12 Oct Genetic Counseling for Ultra-Rare Bleeding Disorders Oct 12, 2022 - Oct 12, 2022 05 Oct Parental perspectives on gene therapy for children with haemophilia: The Exigency Study Oct 5, 2022 - Oct 5, 2022 28 Sep Navigating the Emergency Room Sep 28, 2022 - Sep 28, 2022 21 Sep Comprehensive Pain Management: the Old and the New Sep 21, 2022 - Sep 21, 2022 14 Sep MSKUS Sep 14, 2022 - Sep 14, 2022 17 Aug An exploration of why men with severe haemophilia might not want gene therapy: The exigency study Aug 17, 2022 - Aug 17, 2022 10 Aug 50 Years of the JGP Research Fellowship Aug 10, 2022 - Aug 10, 2022 03 Aug Markers of autoimmunity in immune thrombocytopenia Aug 3, 2022 - Aug 3, 2022 20 Jul VWD and Iron Deficiency Jul 20, 2022 - Jul 20, 2022 13 Jul Quantitative measurements of hemophiliac joint tissues by point-of-care musculoskeletal ultrasound Jul 13, 2022 - Jul 13, 2022 29 Jun The Challenges of Assessing and Managing Pain Jun 29, 2022 - Jun 29, 2022 22 Jun Sickle Cell Disease & Red Blood Cell Transfusion Jun 22, 2022 - Jun 22, 2022 15 Jun Factor product utilization and health outcomes in patients with hemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes Jun 15, 2022 - Jun 15, 2022 08 Jun Lived experiences and barriers to care for men with hemophilia Jun 8, 2022 - Jun 8, 2022 01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022 Pagination First page Previous page Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Next page Last page
25 Jan Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A Jan 25, 2023 - Jan 25, 2023
07 Dec Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays Dec 7, 2022 - Dec 7, 2022
26 Oct Global seroprevalence of pre-existing immunity against AAV5 and other AAV serotypes in people with hemophilia A Oct 26, 2022 - Oct 26, 2022
05 Oct Parental perspectives on gene therapy for children with haemophilia: The Exigency Study Oct 5, 2022 - Oct 5, 2022
17 Aug An exploration of why men with severe haemophilia might not want gene therapy: The exigency study Aug 17, 2022 - Aug 17, 2022
13 Jul Quantitative measurements of hemophiliac joint tissues by point-of-care musculoskeletal ultrasound Jul 13, 2022 - Jul 13, 2022
15 Jun Factor product utilization and health outcomes in patients with hemophilia A and B on extended half-life concentrates: A Canadian observational study of real-world outcomes Jun 15, 2022 - Jun 15, 2022
01 Jun Immune tolerance induction in the era of emicizumab - still the first choice for patients with hemophilia A and inhibitors Jun 1, 2022 - Jun 1, 2022